TW202342466A - 二肽基肽酶抑制劑化合物的鹽及晶型 - Google Patents

二肽基肽酶抑制劑化合物的鹽及晶型 Download PDF

Info

Publication number
TW202342466A
TW202342466A TW112106411A TW112106411A TW202342466A TW 202342466 A TW202342466 A TW 202342466A TW 112106411 A TW112106411 A TW 112106411A TW 112106411 A TW112106411 A TW 112106411A TW 202342466 A TW202342466 A TW 202342466A
Authority
TW
Taiwan
Prior art keywords
crystal form
formula
compound
present
salt
Prior art date
Application number
TW112106411A
Other languages
English (en)
Chinese (zh)
Inventor
范江
竇贏
宫正
朱鳳飛
Original Assignee
大陸商四川海思科製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商四川海思科製藥有限公司 filed Critical 大陸商四川海思科製藥有限公司
Publication of TW202342466A publication Critical patent/TW202342466A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cooling Or The Like Of Semiconductors Or Solid State Devices (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112106411A 2022-02-22 2023-02-22 二肽基肽酶抑制劑化合物的鹽及晶型 TW202342466A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022101608625 2022-02-22
CN202210160862 2022-02-22

Publications (1)

Publication Number Publication Date
TW202342466A true TW202342466A (zh) 2023-11-01

Family

ID=87764787

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112106411A TW202342466A (zh) 2022-02-22 2023-02-22 二肽基肽酶抑制劑化合物的鹽及晶型

Country Status (13)

Country Link
US (1) US20250188067A1 (https=)
EP (1) EP4484414A4 (https=)
JP (1) JP2025508792A (https=)
KR (1) KR20240153351A (https=)
CN (1) CN118660873A (https=)
AU (1) AU2023225835A1 (https=)
CA (1) CA3243683A1 (https=)
CL (1) CL2024002490A1 (https=)
IL (1) IL314852A (https=)
MX (1) MX2024010180A (https=)
TW (1) TW202342466A (https=)
WO (1) WO2023160542A1 (https=)
ZA (1) ZA202407225B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314855A (en) * 2022-02-22 2024-10-01 Haisco Pharmaceuticals Pte Ltd Preparation method of nitrogen-containing heterocyclic compound
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
NO2699580T3 (https=) * 2014-01-24 2018-02-24
CN115996923B (zh) * 2020-08-26 2025-07-18 海思科医药集团股份有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN114106005B (zh) * 2020-08-26 2025-08-01 西藏海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
US20240150335A1 (en) * 2021-02-05 2024-05-09 Medshine Discovery Inc. Fused ring derivatives containing 1,4-oxazepane

Also Published As

Publication number Publication date
EP4484414A4 (en) 2026-01-28
WO2023160542A1 (zh) 2023-08-31
AU2023225835A1 (en) 2024-10-03
ZA202407225B (en) 2025-12-17
CN118660873A (zh) 2024-09-17
EP4484414A1 (en) 2025-01-01
CL2024002490A1 (es) 2024-12-13
MX2024010180A (es) 2024-08-27
JP2025508792A (ja) 2025-04-10
IL314852A (en) 2024-10-01
US20250188067A1 (en) 2025-06-12
KR20240153351A (ko) 2024-10-22
CA3243683A1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
US9562024B2 (en) Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage
JP2022500458A (ja) 置換ピロロピリミジン系ｃｄｋ阻害剤の塩とその結晶および使用
JP2024517496A (ja) Ｒｏｃｋ阻害剤の酸付加塩及び塩の結晶形、組成物並びに薬物用途
TW202333739A (zh) 二肽基肽酶1抑制劑多晶型物及其製備方法和用途
JP6501773B2 (ja) 結晶形態のダサチニブの塩
TW202342466A (zh) 二肽基肽酶抑制劑化合物的鹽及晶型
JP2025535889A (ja) ピリミジン化合物の新規結晶形態、それを含有する医薬組成物、およびその使用方法
KR101557832B1 (ko) (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
CN115413277B (zh) 吡嗪取代的烟酰胺的固体形式及其制备和用途
JP4015954B2 (ja) トシル酸スプラタスト結晶
TWI333856B (en) Crystals of taxane and process for their production
KR20070112381A (ko) 5-[2-아미노-4-(2-푸릴)피리미딘-5-일]-1-메틸피리딘-2(1ｈ)-온의 결정 및 그 제조 방법
CN108699094B (zh) 一种钠依赖性葡萄糖共转运蛋白抑制剂的胺溶剂合物及其制备方法和应用
TW202404961A (zh) 苯并［ｃ］色滿化合物的可藥用鹽、其多晶型及用途
JP2025531538A (ja) イナボグリフロジンの新規な共結晶
CN118561848A (zh) 一种巴瑞克替尼和马来酸的共晶
EA053095B1 (ru) Соль и кристаллическая форма соединения, являющегося ингибитором дипептидилпептидазы
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
JP7776442B2 (ja) （ｒ）－オキシブチニン塩酸塩の多形形態
WO2019149090A1 (zh) 一种尿酸转运体1抑制剂的晶体及其制备方法和用途
CN111349076B (zh) 一种苯并哌啶类衍生物的l-赖氨酸盐的晶型及其制备方法
CN110218209A (zh) 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
TW202535412A (zh) Pde4b抑制劑的晶型及其在醫藥上的用途
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
WO2022199707A1 (zh) 哌马色林药用盐、制备方法、含其的药物组合物及应用